Articles tagged with Melanoma Cells
A new clinical trial has shown promising results with riluzole, a U.S. FDA-approved drug, slowing the growth of late-stage melanoma in human patients. The Phase 0 trial found three solid positive responses in nine patients, indicating potential as an adjunct to surgical treatment for stage 3 or 4 melanoma.
A study led by Mary J. C. Hendrix found that the Lefty protein, secreted only in human embryonic stem cells, inhibits growth and spread of melanoma and breast cancer cells. This breakthrough suggests potential therapeutic modalities for cancer treatment and highlights the utility of isolating factors within the embryonic microenvironment.
Researchers identified a protein, insulin-like growth factor binding protein 7 (IGFBP7), that regulates melanocytes' decision to ward off cancer by entering a programmed hibernation or committing suicide. This discovery offers new hope for treating deadly melanoma by harnessing the body's natural defense pathway.
Researchers developed a mutated anthrax toxin that targets melanoma cells, with 100% of mice tolerated lethal doses. The toxin was more specific and effective than natural toxin, inhibiting angiogenesis and killing other tumors like colon and lung.
Researchers found that bortezomib selectively inhibits melanoma tumor cells by overactivating the cancer-promoting gene c-MYC, leading to increased production of NOXA and promoting cell death. The study suggests a novel treatment strategy for various types of cancer.
High levels of CD200 expression in melanomas represses activation of antitumor T cell immune responses by dendritic cells. Targeting the interaction between CD200 and its receptor may provide a new treatment approach for metastatic melanoma.
The experimental drug STA-4783 has been shown to delay cancer progression and prolong patient lives by inducing oxidative stress in cancer cells. In a randomized trial, patients treated with the combination of STA-4783 and chemotherapy lived up to 12 months after diagnosis, compared to 7.8 months for those receiving only chemotherapy.
Researchers have identified a promising drug combination that may help treat metastatic uveal melanoma, a rare and aggressive form of the disease. The combination of decitabine and interferon gamma has shown to cause cancer cell death in human cell lines derived from patients with uveal melanoma.
Researchers found that an important melanoma treatment has little effect on cancer cells themselves, but instead boosts immune system cells. The study highlights the need to develop ways to make melanoma cells more vulnerable to the drug or overcome the block within cells that prevents them from responding.
A 12-year review of skin cancer data in Northern Ireland found that wealthy individuals and older adults are disproportionately affected. The study also shows a significant increase in skin cancer rates, with malignant melanoma being the most common serious form of skin cancer.
A study published in The American Journal of Pathology found that a specific enzyme helps protect against tumor growth by enhancing the immune response. Mice with high levels of this enzyme in their macrophages were resistant to melanoma and lymphoma, demonstrating its potential as a new cancer therapy.
Researchers found that immune cells in most people with melanoma fail to respond properly to interferon, leading to impaired immune function. This discovery could pave the way for more effective treatment options, including vaccine therapies.
A study by Dr. Mary J.C. Hendrix found that inhibiting Nodal signaling in aggressive melanoma cells can reverse their invasiveness and tumor formation, reverting them to a more benign skin cell type. This discovery provides a promising new target for regulating tumor progression and metastasis.
Scientists have discovered that a cell-signaling molecule Akt plays a key role in the progression of melanomas from non-invasive to invasive cancers. Understanding this molecular difference could lead to new targets for treating advanced stage melanoma, with a survival rate of 98% for radial melanomas on the surface of the skin.
A phase II trial of the drug denileukin diftitox found that it depletes regulatory T cells, allowing CD8+ T lymphocytes to attack melanoma cells. Patients with stage IV disease experienced significant regression or stabilization of tumors and metastases.
Researchers aim to create a topical cream that increases skin pigmentation and repairs DNA damage caused by UV radiation, reducing skin cancer risk. The project builds on previous findings that alpha-MSH can reverse the effects of UV radiation on skin cells.
Researchers have developed a new method to detect metastasizing melanoma cells in the blood using photoacoustic detection, which can identify as few as 10 cancer cells. The technique uses laser techniques and ultrasound methods to emit noise from cancer cells, allowing for early diagnosis and treatment.
Researchers at UVA Health System have discovered cancer-testis antigens, called SPANX proteins, which could selectively kill melanoma tumors while sparing the rest of the body's tissues. These antigens may also help develop a vaccine to stimulate the immune system to attack and suppress melanoma tumors.
Researchers found that melanocytes use a mechanism called premature senescence to prevent cancer-causing mutations from triggering melanoma. This process involves the endoplasmic reticulum, which senses oncogene activity and triggers a response that stops cell division and prevents tumor growth.
Researchers at Dana-Farber Cancer Institute developed a way to protect fair-skinned individuals from skin cancer using medicinally-induced tans. The study, published in Nature, involved applying a cream that mimicked the process of ultraviolet rays triggering pigmentation, suggesting a novel approach to preventing melanoma.
Researchers successfully transformed normal immune cells into tumor fighters, demonstrating their ability to persist in the body and shrink large tumors in humans. The engineered cells were found to show signs of persistence in 15 of the 17 patients in the study, with two patients seeing significant tumor shrinkage.
Researchers discovered that malignant melanoma cells secrete Nodal, a protein essential for proper embryo development, inducing abnormal skull and backbone formation in zebrafish embryos. Blocking Nodal signaling reduced melanoma cell invasiveness and promoted reversion to normal skin cells.
The Baylor Institute for Immunology Research has been awarded a $3 million grant to develop vaccines against melanoma, a deadly form of skin cancer. The research will focus on using dendritic cells to modulate the immune system and stimulate an anti-cancer response.
Researchers have defined normal melanocyte numbers in sun-exposed skin, distinguishing sun damage from early melanoma. This finding allows for less tissue removal and trauma to the skin.
Researchers found that suppressing telomerase, a key enzyme in cancer cell growth, can inhibit the spread of melanoma. By reducing glucose metabolism, cancer cells lose their ability to metastasize and regain lost pigmentation.
A new study reveals that targeted melanoma education of high-risk groups leads to sustained improvements in skin self-examination rates. The intervention, which included personalized educational materials and counseling sessions, significantly increased the number of siblings who performed regular skin self-examinations.
A community-based education campaign significantly increased skin cancer screening rates in men over 50, with a two-fold increase in self-screening and four-fold increase in physician-screening. Men who recognized personal risk factors or had previously removed skin lesions were more likely to undergo screening.
Scientists have identified a novel gene NEDD9 that facilitates the spread of malignant melanoma. This gene is abnormally abundant in more than a third of melanomas that have metastasized, but not in primary melanomas.
A review of 1,690 melanoma cases in Miami-Dade County found that Hispanic and black patients were more likely to have advanced-stage melanomas than white patients. This disparity may contribute to lower survival rates among blacks and Hispanics.
Breakthroughs in melanoma research suggest optimism for future cures, with artificial skin models enabling the study of tumor interactions and immune system responses. A novel vaccine approach also shows promise in treating melanoma by stimulating killer T cells to attack cancerous cells.
Researchers identified a shared causative mechanism among malignant melanoma, soft-tissue sarcomas, and pediatric renal carcinoma, suggesting a common therapeutic strategy. The discovery centers on the MiT transcription factor family, which regulates growth genes and is abnormally expressed in these cancers.
Researchers found that 20% of participants developed additional melanoma within one year and 27% within two years after initial diagnosis. Those with atypical moles had a higher risk of developing additional melanomas, with those having three or more atypical moles being four times more likely to develop multiple tumors.
Researchers developed a vaccine strategy using the BRAFV600E peptide to stimulate killer T cells, showing potential for treating approximately a third of melanoma patients. The approach's specificity reduces toxicity and targets only cancer cells.
Protein sorting in pigment cells plays a crucial role in the development of diseases such as melanoma and Alzheimer's. The study reveals that Pmel17 proteins are sorted to the melanosome through endosomes, similar to other amyloid proteins.
Using a chick model, researchers demonstrated that malignant melanoma cells can respond to and be influenced by the embryonic neural-crest-rich microenvironment. This discovery may hold promise for developing new treatments for metastatic melanoma.
Researchers found that nonmelanoma skin cancers are strongly associated with UVB radiation, but melanoma patients have a different response. The study suggests that melanoma may be resistant to UVB-induced chromosomal breaks, increasing the risk of more serious cancer.
Research found a high number of chromid breaks associated with increased risk of nonmelanoma skin cancers and basal cell carcinomas, while melanoma risk was not linked. UV-B radiation sensitivity also interacted with other risk factors for squamous cell and basal cell carcinomas.
Researchers at Northwestern University discovered that human embryonic stem cells can reprogram metastatic melanoma cells to a more normal state by mimicking their natural microenvironment. The findings suggest a new approach for investigating the effects of identifying key factors in reversing tumor cell properties.
Researchers developed a model that reprograms benign skin cells to express genes associated with aggressive melanoma cells, highlighting the role of tumor cell microenvironment in transformation. The study provides potential therapeutic strategies to inhibit melanoma spread.
A new vaccine-based approach has been shown to prolong disease progression in patients with renal cancer and malignant melanoma. The therapy, which uses latex or silica beads, was found to stabilise and control disease for an average of one year. In contrast, standard treatments have limited efficacy and are often toxic.
Researchers at Northwestern University have discovered a potential target for preventing metastatic melanoma, the cancer's ability to spread and be fatal. The study identified focal adhesion kinase (FAK) as a key player in promoting aggressive melanoma behavior.
Researchers pinpoint CD36 as the first candidate for detecting fatty acids in the oral cavity, influencing digestive physiology and potentially increasing obesity risk. The study also reveals an alteration in the fat perception system may impact HIV transmission through human milk.
Researchers found that activated STAT5 in melanoma cells blocks interferon's ability to inhibit growth, leading to frequent treatment failure. Analyzing STAT5 status may help personalize therapies for advanced melanoma patients.
Researchers have identified distinct patterns of responses in patient cells after vaccination against melanoma, which may help monitor treatment response. The study found that certain compounds were secreted by cells in patients whose tumors did not grow after vaccination.
Melanoma cells can efficiently spread due to reactivation of dormant Slug gene, which enables swift travel through the body. This discovery sheds light on why melanoma metastasizes at an earlier stage than other cancers.
A randomized controlled trial found that high-protection sunscreen did not influence the duration of sunbathing. In fact, the study discovered that people tend to self-regulate their sun protection with sunscreens by adapting the amount of sunscreen used based on its SPF level.
Researchers have found curcumin to be an effective compound in reducing cell viability and inducing apoptosis in melanoma cell lines. The study reveals that curcumin suppresses specific proteins involved in preventing apoptosis, suggesting its potential as a potent anti-cancer agent.
Researchers discovered an overcopied MITF oncogene in melanoma cells, associated with poorer treatment outcomes. Targeting this gene may provide a new target for highly specific therapies for metastatic melanoma patients.
Researchers found that zebrafish embryos with human metastatic melanoma cells suppress tumor development, suggesting potential for new cancer therapies. The study provides a powerful model for investigating tumor-microenvironment interactions and reversing the aggressive phenotype of cancer cells.
Researchers generated human skin tissue with cancer-associated genes to study melanoma development. They found that specific gene combinations, such as Ras and hTERT, induced invasive melanoma growth in human tissue.
A novel technique developed by Stanford researchers allows scientists to distinguish between possible cancer-causing genes and those that are harmless. Mutations in the PI3K gene were found to be a primary driver of melanoma, while a mutation in the B-Raf gene did not cause cancer despite being commonly associated with the disease.
Researchers developed new methods for diagnosing cancer based on genomic DNA analysis, which detects changes in chromatin structure and cell interaction with the microenvironment. These findings may lead to the design of new cancer therapeutic agents.
Researchers discovered that targeting mutant B-Raf protein can prevent the spread of melanoma and halt tumor growth. Lowering mutant B-Raf activity reduced melanoma development in human cells, providing a potential breakthrough for treating this aggressive form of skin cancer.
Researchers genetically engineered zebrafish to develop black-pigmented moles with mutated human BRAF and p53 genes. The study shows that BRAF mutations are necessary for mole development, but insufficient for cancer. The model provides insights into how gene mutations contribute to melanoma
Researchers found that vaccination against tumor-specific proteins can reinvigorate existing T cells, allowing them to attack tumors. This breakthrough suggests a new approach to treating skin cancer by targeting the immune system's natural defense mechanisms.
Researchers at Dana-Farber Cancer Institute found that the loss of hair color is caused by the gradual dying off of adult stem cells, which become depleted and make errors. This discovery may lead to a better understanding of the underlying mechanism of graying and potentially inform treatment for malignant melanoma.
Researchers found that blocking CDK2 activity may control deadly skin cancer without harming normal cells. The study's findings suggest a therapeutic window for a drug that suppresses melanoma growth by shutting down CDK2 activity, potentially leading to a new treatment option.
A recent study suggests that Akt3 protein is key to melanoma's resistance to chemotherapy, promoting tumor cell survival and development in 43-60% of non-inherited melanomas. Lowering Akt3 activity can reduce tumor-creating potential and make cancer cells more susceptible to signals inducing apoptosis.
A new study of pesticide applicators found an increased incidence of lung cancer associated with chlorpyrifos exposure. Meanwhile, research on celecoxib-induced apoptosis in human lung cancer cells and the molecular mechanism of DNA repair proteins' relation to malignant melanoma are also reported.
Researchers found a correlation between the presence of the CXCR3 protein and increased survival in Stage III metastatic melanoma patients. This discovery may lead to improved vaccines that 'turn-on' cancer-killing immune cells and instruct them to find tumors.